Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Almac Adds Illumina NovaSeq 6000 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Almac Adds Illumina NovaSeq 6000

The sequencer aims to benefit Biopharma clients’ biomarker discovery and clinical trial projects

By: Betsy Louda

, Contract Pharma

Almac Diagnostic Services has announced a significant investment in a new Illumina NovaSeq 6000 sequencer which will benefit Biopharma clients’ biomarker discovery and clinical trial projects.

 
The addition of the NovaSeq’s powerful processing capabilities to Almac’s existing range of NGS platform offerings will allow for larger sample runs, greater read depth, and faster speeds. The new instrument will also ultimately reduce sample turnaround times and increase variant detection quality and accuracy for clients.
 
With the NovaSeq, Almac will be able to sequence the transcriptomes of up to ~384 samples, per run (dual flow cell, 50M reads per sample) in a timeframe as short as 36 hours. The NovaSeq provides scalable throughput and flexibility for virtually any sequencing method, genome, and scale of project. To accommodate NovaSeq’s high capacity and efficiency, Almac has also invested in appropriate informatics infrastructure and installed high speed uplinks to cloud based providers.
 
The NovaSeq will form an integral part of Almac’s current DNA and RNA Sequencing offerings and future offerings for Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES).  
 
Michael Sloan, global vice president of Commercial Operations, Almac Diagnostic Services said, “We are excited about the potential benefits the NovaSeq will be able to bring to our customers with its sequencing capabilities enhancing our current DNA and RNA NGS panel offerings to the market. We are positioning ourselves at the cutting edge of NGS diagnostics and the investment in this new NGS platform will help Almac to continue to play a leading role within stratified medicine.”      
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics